Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

14 results about "Prochirality" patented technology

In stereochemistry, prochiral molecules are those that can be converted from achiral to chiral in a single step. An achiral species which can be converted to a chiral in two steps is called proprochiral.

Carbonyl reductase mutant as well as preparation method and application thereof

ActiveCN120905170ABacteriaMicroorganism based processesChemical compoundCarbonyl Reductase
The invention discloses a carbonyl reductase mutant as well as a preparation method and application thereof, and belongs to the technical field of gene engineering and enzyme engineering. According to the invention, wild-type carbonyl reductase of Stachybotrys chlorohallonata is taken as an evolution template, and a plurality of mutants with catalytic activity, thermal stability and substrate spectrum obviously superior to those of the wild-type carbonyl reductase are obtained through an enzyme engineering technology. The carbonyl reductase mutant can catalyze various prochiral carbonyl compounds to obtain chiral alcohol with high stereoselectivity (ee is greater than 99%). The carbonyl reductase mutant provides a novel, efficient and environment-friendly technical route for industrial production of chiral alcohol products, and has very high industrial application potential.
Owner:PHARMARON NINGBO CO LTD +1

Carbonyl reductase mutant, gene, engineering bacterium and application

The invention relates to the technical field of biology, in particular to a carbonyl reductase mutant, a gene, an engineering bacterium and application. The amino acid sequence of the carbonyl reductase mutant is shown as SEQ ID NO: 1, the catalytic efficiency of asymmetric reductive hydrogenation of prochiral ketone compounds is improved, the stereoselectivity of chiral hydroxyl compounds formed through catalysis is improved, and the synthesis efficiency of (S)-1-(5-fluoro-2-iodophenyl) ethanol is improved.
Owner:JIAXING SYNBIOLAB TECHNOLOGY CO LTD

Ruthenium-carbon hydrogenation catalyst based on chiral diphosphine ligand modification and preparation method and application thereof

The invention relates to the technical field of catalysts, in particular to a chiral diphosphine ligand modification-based ruthenium-carbon hydrogenation catalyst as well as a preparation method and application thereof. The method comprises the following steps: preparing a nitrogen-containing defect carbon carrier; loading ruthenium and reducing; pre-coating the confinement by using an ionic liquid A; introducing a chloride ion template microenvironment; carrying out coordination with a chiral diphosphine ligand; weak coordination anion sizing is realized through the treatment of bis (trifluoromethanesulfonyl) imide silver; and finally introducing chiral ionic liquid B to construct an outer network. The catalyst realizes high enantioselective conversion of a prochiral substrate while maintaining high hydrogenation activity through a multi-layer chiral microenvironment synergistic effect, is excellent in cycling stability, and solves the technical problem that the activity and selectivity of a heterogeneous chiral catalyst are difficult to consider at the same time.
Owner:SHAANXI ROCK NEW MATERIALS CO LTD

P-chiral phosphine oxides containing alkynyl or triazole functional groups, and methods of making and using the same

The application discloses a five-membered ring containing alkynyl or triazole functional group P The chiral phosphine oxide compound is obtained through Domino Heck-Sonogashira cascade reaction by taking a prochiral tertiary phosphine oxide compound containing a double ethylene group and phenylacetylene as raw materials, transition metal palladium catalyst and chiral TADDOL phosphoramidite ligand under the protection of inert gas P The chiral phosphine oxide compound has a product yield of 96% and an enantioselectivity ee value of 99%, and a diastereoselectivity dr value of greater than 20:1. The application adopts an asymmetric desymmetrization strategy, uses a Heck reaction to start and a Sonogashira reaction to end a cascade reaction, simultaneously constructs P The chiral and quaternary carbon chiral center has mild reaction conditions, simple operation and good substrate universality, provides a compound skeleton with diversity, and is successfully applied to a palladium-catalyzed asymmetric allyl substitution reaction as a chiral ligand.
Owner:GUANGDONG UNIV OF TECH

Alcohol dehydrogenase mutant, engineering bacterium and application in synthesis of sinobamate intermediate

The invention discloses an ethanol dehydrogenase mutant, engineering bacteria and application in synthesis of a sinobamate intermediate, the ethanol dehydrogenase mutant is utilized to catalyze prochiral ketone (B) to synthesize chiral alcohol (A), the method is high in substrate concentration, simple and convenient in post-treatment step and more suitable for industrial large-scale production, and the problems that in the prior art, the substrate concentration is not high, and the yield is high are solved. Post-treatment is complicated, and the like.
Owner:HANGZHOU WENDEJIE BIOTECHNOLOGY CO LTD

Chiral ferrocene skeleton PNNO tetradentate ligand and application thereof in asymmetric hydrogenation reaction

The invention relates to a chiral ferrocene skeleton PNNO tetradentate ligand and application thereof in asymmetric hydrogenation reaction. The ligand has the advantages of simple synthesis, good stability, high selectivity and the like. A metal complex of the ligand shows very excellent catalytic activity and extremely high enantioselectivity in an asymmetric hydrogenation reaction of ketone, can efficiently catalyze reduction of prochiral ketones such as aryl alkyl ketone, heteroaryl alkyl ketone, aryl (hetero) aryl ketone, aliphatic ketone and the like into corresponding chiral alcohol, and has huge industrial application potential.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Chiral triazol-oxazoline compound and preparation method and application thereof

ActiveCN117447462BLow raw material costfew synthetic stepsPtru catalystOrganic synthesis
The application relates to a chiral triazole-oxazoline compound and a preparation method and application thereof, and belongs to the technical field of organic synthesis. The chiral triazole-oxazoline compound has the structural formula: the preparation method comprises the steps of click reaction, triazole N2 substitution reaction, Suzuki coupling, triazole ester hydrolysis, amidation with a chiral amine alcohol and dehydration condensation. After a chiral triazole-oxazoline compound and a palladium salt compound are added to generate a catalyst in situ, asymmetric addition of aryl boronic acid on a carbon-carbon double bond of a prochiral organic compound is carried out to prepare a chiral organic compound. The application has the advantages of low raw material cost, few synthesis steps, low experiment site requirement, relatively mild reaction conditions and simple operation for preparing the novel triazole-oxazoline compound.
Owner:JILIN UNIVERSITY

Transaminase mutant and its use in the preparation of a sitagliptin intermediate

UndeterminedES3073041T3ThreonineTyrosine
A mutant transaminase and its use in the preparation of a sitagliptin intermediate are provided. The mutant is obtained by substituting tyrosine at position 74 with proline, glutamic acid at position 228 with aspartic acid, leucine at position 254 with alanine, and methionine at position 290 with threonine in the amino acid sequence shown in SEQ ID NO: 2. The sitagliptin intermediate or sitagliptin ester is prepared using wet thallus or a pure enzyme obtained by fermentation and culture of genetically modified bacteria containing a gene encoding the mutant transaminase as a biocatalyst, and using a ketone precursor of the sitagliptin intermediate or a prochiral carbonyl compound as a substrate. The overall yield is approximately 82%, and the ee value of the product can reach up to 99%.

Asymmetric carbon-hydrogen bond boronation reaction catalyst and preparation method of chiral dicyclobutane

The invention relates to the technical field of organic synthesis, and provides an asymmetric carbon-hydrogen bond boronation reaction catalyst and a preparation method of chiral dicyclobutane. A catalyst composed of a chiral boron-based ligand and an iridium salt is adopted to catalyze an asymmetric carbon-hydrogen bond boronation reaction of prochiral dicyclobutane, in a reaction system, the iridium salt and the chiral boron-based ligand are combined to form a complex, the complex reacts with B2pin2 to form an active intermediate, and the active intermediate is separated from the chiral boron-based ligand to form the chiral dicyclobutane. Then the iridium center and a carbon-hydrogen bond of a 3-substituted dicyclobutane-1-formamide compound are subjected to an asymmetric oxidative addition reaction to form an iridium-carbon bond, then reduction elimination is carried out, and the target product chiral dicyclobutane is generated. The reaction condition for constructing the chiral dicyclobutane is mild, the selectivity is high, the enantioselectivity is 95% or above, the substrate universality is wide, and chiral dicyclobutane compounds of different structures can be synthesized.
Owner:LANZHOU INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES

Method for preparing chiral lactam by organic catalysis of desymmetry of prochiral cyclic ketone

The invention discloses a method for preparing chiral lactam from prochiral ketone, and belongs to the technical field of chemical synthesis. According to the method, chlorobenzene or toluene or a chlorobenzene / diethyl ether mixed solution is used as a solvent, under the action of a chiral catalyst, prochiral cyclic ketone and sulfonyl hydroxylamine are subjected to a desymmetrical nitrogen atom insertion reaction at-78 DEG C to 25 DEG C, high-stereoselectivity chiral lactam is prepared in one step, and the reaction time is 2-8 h. The method has the advantages that the raw materials are low in price and easy to obtain, the chiral catalyst is commercially available and small in dosage, the product has excellent stereoselectivity, post-treatment is simple and convenient, and a novel green and economical way with wide industrial application prospects is provided for synthesis of chiral drugs and fine chemicals.
Owner:CHONGQING COLLEGE OF ELECTRONICS ENG +1

A ruthenium carbon hydrogenation catalyst based on chiral diphosphine ligand modification, and a preparation method and application thereof

The present application relates to the technical field of catalyst, in particular to a ruthenium carbon hydrogenation catalyst based on chiral diphosphine ligand modification and its preparation method and application. The method comprises the following steps: preparing a nitrogen-defect-containing carbon carrier; loading ruthenium and reducing; pre-coating a confinement layer by using ionic liquid A; introducing a chloride ion template microenvironment; coordinating with a chiral diphosphine ligand; achieving weakly coordinated anion shaping by treating with bis(trifluoromethanesulfonyl) imide silver; and finally introducing chiral ionic liquid B to construct an outer network. The catalyst realizes high enantioselective conversion of prochiral substrates through the synergistic effect of multi-level chiral microenvironments while maintaining high hydrogenation activity, and has excellent cycle stability, solving the technical problem that the activity and selectivity of non-homogeneous chiral catalysts are difficult to balance.
Owner:SHAANXI ROCK NEW MATERIALS CO LTD

Carbonyl reductase mutant as well as preparation method and application thereof

The invention is applicable to the technical field of enzyme engineering, and provides a carbonyl reductase mutant as well as a preparation method and application thereof, the carbonyl reductase mutant is used for asymmetrically and specifically catalyzing a prochiral carbonyl compound to generate corresponding chiral alcohol; the carbonyl reductase mutant takes the sequence of the carbonyl reductase polypeptide as a starting sequence, and compared with the sequence of the carbonyl reductase polypeptide, the carbonyl reductase mutant contains one or more residue differences; the amino acid sequence of the carbonyl reductase polypeptide is as shown in SEQ ID NO. 2 in the sequence table. The enzyme activity of the carbonyl reductase mutant obtained by carrying out site-directed mutagenesis on the carbonyl reductase is far higher than that of the carbonyl reductase which is not mutated; the carbonyl reductase mutant can be used for specifically catalyzing a prochiral carbonyl compound into a chiral product of a required Ritlecitinib medical intermediate, so that the carbonyl reductase mutant has a wide application value and a very strong practical value in the synthesis application of a medicament Ritlecitinib for treating alopecia areata.
Owner:ANHUI MEDICAL UNIV

Process for the preparation of chiral homopiperazine-5-carboxylic acid and its fluorenylmethoxycarbonyl derivatives

The present application relates to a preparation method of chiral homomorpholine-5-methanoic acid and fluorenylmethoxycarbonyl derivatives thereof, and mainly solves the technical problem that there is no industrial synthesis method for chiral homomorpholine-5-methanoic acid at present. The preparation method comprises the following steps: condensing benzyloxyethyloxyethyl bromide and 2-acetylamino malonic acid diethyl ester, hydrolyzing to obtain compound I, and enzymatically separating to obtain compound II and compound III; after Boc protection and methyl ester of compound II, debenzyl, sulfonylation, iodination, obtaining protected compound V, after deprotection, ring formation under alkaline conditions to obtain compound VII, and finally Fmoc protection to obtain compound VIII. The whole process is a conventional reaction, does not need fine operation, does not need deep low temperature reaction, does not need expensive palladium coupling reagent or flammable and explosive metal organic reagent, and can be mass produced.
Owner:JILL PEPTIDE BIOPHARMACEUTICAL (DALIAN) CO LTD